Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty - The EMPAR study

被引:118
作者
Cairns, JA
Gill, J
Morton, B
Roberts, R
Gent, M
Hirsh, J
Holder, D
Finnie, K
Marquis, JF
Naqvi, S
Cohen, E
机构
[1] MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON L8N 3Z5, CANADA
[2] UNIV OTTAWA, DEPT MED, OTTAWA, ON, CANADA
[3] UNIV WESTERN ONTARIO, LONDON, ON N6A 3K7, CANADA
[4] UNIV TORONTO, TORONTO, ON M5S 1A1, CANADA
关键词
angioplasty; restenosis; fish oils; heparin; coronary disease;
D O I
10.1161/01.CIR.94.7.1553
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Percutaneous transluminal coronary angioplasty (PTCA) is complicated by restenosis within 6 months in >40% of patients. Theoretical, animal experimental, and human epidemiological and clinical trial findings have suggested that fish oils (n-3) might reduce restenosis. Low-molecular-weight heparin (LMWH) has reduced cellular proliferation and restenosis in several experimental systems. Methods and Results We randomized 814 patients to fish oils (5.4 g n-3 fatty acids) or placebo a median of 6 days before PTCA and continued for 18 weeks. At the time of sheath removal, 653 patients with at least one successfully dilated lesion were randomized to LMWH (30 mg SC BID) or control for 6 weeks in a 2 x 2 factorial design. Follow-up with quantitative coronary angiography (QCA; target, 18 weeks) was interpretable on 96% of these patients. Restenosis rates per patient were for n-3, 46.5%; placebo, 44.7%; LMWH, 45.8%; and control, 45.4%. Restenosis rates per lesion were for n-3, 39.7%; placebo, 38.7%; LMWH, 38%; and control, 40.4%. At follow-up QCA, mean minimal lumen diameters were (mm) for n-3, 1.12; placebo, 1.10; LMWH, 1.12; and control, 1.10. Fifteen percent of patients permanently discontinued n-3/placebo before study completion, and 21% of patients discontinued LMWH early. There were no significant differences in the occurrences of ischemic events. Bleeding was more common with LMWH, usually was mild, and led to early discontinuation of study medication in only 0.9% of patients. Gastrointestinal side effects were more common in patients receiving n-3 than placebo. Conclusions There is no evidence for a clinically important reduction of PTCA restenosis in this trial by either n-3 or LMWH. Evaluation of the results for n-3 in the context of previously published data on the reduction of PTCA restenosis indicates that n-3 is not efficacious and that further trials are unwarranted.
引用
收藏
页码:1553 / 1560
页数:8
相关论文
共 40 条
  • [31] USEFULNESS OF FISH OIL SUPPLEMENTS IN PREVENTING CLINICAL-EVIDENCE OF RESTENOSIS AFTER PERCUTANEOUS TRANS-LUMINAL CORONARY ANGIOPLASTY
    MILNER, MR
    GALLINO, RA
    LEFFINGWELL, A
    PICHARD, AD
    BROOKSROBINSON, S
    ROSENBERG, J
    LITTLE, T
    LINDSAY, J
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1989, 64 (05) : 294 - 299
  • [32] EFFECT OF EICOSAPENTAENOIC ACID ON RESTENOSIS RATE, CLINICAL COURSE AND BLOOD-LIPIDS IN PATIENTS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY
    NYE, ER
    ABLETT, MB
    ROBERTSON, MC
    ILSLEY, CDJ
    SUTHERLAND, WHF
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1990, 20 (04): : 549 - 552
  • [33] PETO R, 1978, BIOMEDICINE, V28, P849
  • [34] HEPARIN INHIBITION OF SMOOTH-MUSCLE CELL-PROLIFERATION - A CELLULAR SITE OF ACTION
    REILLY, CF
    FRITZE, LMS
    ROSENBERG, RD
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1986, 129 (01) : 11 - 19
  • [35] REIS GJ, 1989, LANCET, V2, P177
  • [36] GUIDELINES FOR PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY - A REPORT OF THE AMERICAN-COLLEGE-OF-CARDIOLOGY AMERICAN-HEART-ASSOCIATION TASK-FORCE ON ASSESSMENT OF DIAGNOSTIC AND THERAPEUTIC CARDIOVASCULAR PROCEDURES (COMMITTEE ON PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY)
    RYAN, TJ
    BAUMAN, WB
    KENNEDY, JW
    KEREIAKES, DJ
    KING, SB
    MCCALLISTER, BD
    SMITH, SC
    ULLYOT, DJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 22 (07) : 2033 - 2054
  • [37] PHARMACOLOGICAL THERAPY AFTER CORONARY ANGIOPLASTY - EARLY EXPERIENCE WITH LOW-MOLECULAR-WEIGHT HEPARIN FOR PROPHYLAXIS OF REOCCLUSION
    SCHMIDT, T
    TEBBE, U
    SCHRADER, J
    BRUNE, S
    KREUZER, H
    [J]. KLINISCHE WOCHENSCHRIFT, 1990, 68 (05): : 294 - 294
  • [38] A COMPARISON OF BALLOON-EXPANDABLE-STENT IMPLANTATION WITH BALLOON ANGIOPLASTY IN PATIENTS WITH CORONARY-ARTERY DISEASE
    SERRUYS, PW
    DEJAEGERE, P
    KIEMENEIJ, F
    MACAYA, C
    RUTSCH, W
    HEYNDRICKX, G
    EMANUELSSON, H
    MARCO, J
    LEGRAND, V
    MATERNE, P
    BELARDI, J
    SIGWART, U
    COLOMBO, A
    GOY, JJ
    VANDENHEUVEL, P
    DELCAN, J
    MOREL, MA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (08) : 489 - 495
  • [39] SLACK JD, 1987, J AM COLL CARDIOL, V9, pA64
  • [40] INHIBITION OF ATHEROSCLEROSIS BY COD-LIVER OIL IN A HYPERLIPIDEMIC SWINE MODEL
    WEINER, BH
    OCKENE, IS
    LEVINE, PH
    CUENOUD, HF
    FISHER, M
    JOHNSON, BF
    DAOUD, AS
    JARMOLYCH, J
    HOSMER, D
    JOHNSON, MH
    NATALE, A
    VAUDREUIL, C
    HOOGASIAN, JJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (14) : 841 - 846